Endra Life Sciences Inc (NDRA) Stock Price, Quote & News

Company Profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and ti...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 734 335 0468

Website: endrainc.com

Address:

3600 Green Court, Suite 350, Ann Arbor, United States

Buylocal Jun. 5 at 5:04 PM

$NDRA 6th time suckers took the bait.

0 · Reply

TradingTipsMaster Jun. 4 at 7:04 PM

$NDRA

0 · Reply

supplySHOCK Jun. 4 at 10:17 AM

$NDRA $MODD $BOLT $ATXG ability

0 · Reply

supplySHOCK Jun. 3 at 10:17 PM

$GURE $DXST $NDRA $MODD fuze

0 · Reply

Pagal22 May. 30 at 4:14 PM

$NDRA

0 · Reply

Pagal22 May. 30 at 4:14 PM

$NDRA

0 · Reply

yellowjacker May. 30 at 12:18 PM

$NDRA The raising of funds was put in place to keep NDRA Nasdaq compliant. NDRA still needs a buyer or partner sooner rather than later, as they are running out of money. The investment firm that loaned them the money also agreed to further funding as long as NDRA stays on this path. You don't want to lose your Nasdaq compliants right before you are making a deal.

0 · Reply

Finanz May. 29 at 3:51 PM

$NDRA Dilution ENDRA raised approximately $3.8 million in a May 27, 2026 private placement of stock, prefunded warrants, and common warrants, with proceeds earmarked for working capital and corporate purposes under specific exercisability and ownership limits. A concurrent side letter imposes cash segregation, grants the investor a board observer, and ties repayment to strategic alternatives, supporting ENDRA’s effort to regain and maintain Nasdaq equity compliance after falling below listing requirements in April 2026.

0 · Reply

focafoca99 May. 28 at 10:16 AM

$NDRA has entered a $3.8 million private placement, issuing 578,387 shares and warrants to raise capital.

0 · Reply

Run_Like_Hell May. 27 at 11:03 PM

$NDRA was burned years ago, did these losers ever get fda approval for their liver scanner thingy?

0 · Reply

Endra Life Sciences reports Q1 EPS ($1.09) vs. ($1.86) last year

May 18, 2026, 8:00 AM EDT - 19 days ago

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 7:00 AM EDT - 22 days ago

ENDRA Life Sciences Quarterly report: Q1 2026

2026-05-14T16:56:55.000Z - 23 days ago

Endra Life Sciences reports multi-site validation of TAEUS Liver device

May 14, 2026, 8:00 AM EDT - 23 days ago

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

2026-05-13T19:50:08.000Z - 23 days ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

2026-05-13T19:48:18.000Z - 23 days ago

ENDRA Life Sciences Inc trading resumes

2026-03-31T20:12:41.000Z - 2 months ago

Endra Life Sciences reports Q4 EPS ($8.93) vs ($56.94) last year

Mar 31, 2026, 4:05 PM EDT - 2 months ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 31, 2026, 4:00 PM EDT - 2 months ago

ENDRA Life Sciences Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 2 months ago

ENDRA Life Sciences Earnings release: Q4 2025

2026-03-25T12:06:25.000Z - 2 months ago

Endra Life Sciences initiates review of strategic alternatives

Mar 25, 2026, 8:00 AM EDT - 2 months ago

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

2026-02-26T14:33:33.000Z - 3 months ago

Endra Life Sciences announces favorable TAEUS liver device study results

Feb 26, 2026, 8:00 AM EST - 3 months ago

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

2025-12-04T13:20:28.000Z - 6 months ago

Endra Life Sciences announces results from Taeus Liver device feasibility study

Dec 4, 2025, 8:00 AM EST - 6 months ago

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Nov 20, 2025, 8:00 AM EST - 7 months ago

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Nov 17, 2025, 8:00 AM EST - 7 months ago

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Nov 14, 2025, 7:00 AM EST - 7 months ago

ENDRA Life Sciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

ENDRA Life Sciences Quarterly report: Q3 2025

2025-11-13T14:25:52.000Z - 7 months ago

Endra Life Sciences commences staking of HYPE digital asset holdings

Nov 13, 2025, 8:00 AM EST - 7 months ago

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

2025-11-06T22:05:26.000Z - 7 months ago

Endra Life Sciences files to sell 2.68M shares of common stock for holders

Nov 6, 2025, 7:00 AM EST - 7 months ago

ENDRA Life Sciences Registration statement: Registration Filing

Oct 28, 2025, 8:00 AM EDT - 7 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 7 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 23, 2025, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Oct 17, 2025, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Oct 13, 2025, 8:00 AM EDT - 8 months ago

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

2025-08-14T20:15:23.000Z - 10 months ago

Endra Life Sciences reports Q2 EPS ($1.71) vs. (8c) last year

Aug 14, 2025, 4:05 PM EDT - 10 months ago

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:00 PM EDT - 10 months ago

ENDRA Life Sciences Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

ENDRA Life Sciences Quarterly report: Q2 2025

Jul 25, 2025, 8:00 AM EDT - 11 months ago

ENDRA Life Sciences Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 11 months ago

ENDRA Life Sciences Registration statement: Registration Filing

2025-07-09T13:15:12.000Z - 11 months ago

Endra Life Sciences files to sell 15.7M shares of common stock

Jul 9, 2025, 8:00 AM EDT - 11 months ago

ENDRA Life Sciences Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

2025-05-15T20:15:45.000Z - 1 year ago

Endra Life Sciences reports Q1 EPS ($1.86) vs ($449.58) last year

May 15, 2025, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025, 12:30 PM EDT - 1 year ago

ENDRA Life Sciences Quarterly report: Q1 2025

May 15, 2025, 12:30 PM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q1 2025

2025-05-09T14:02:48.000Z - 1 year ago

ENDRA Life Sciences Inc trading resumes

2025-05-09T13:58:10.000Z - 1 year ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

Mar 31, 2025, 9:00 AM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q4 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

ENDRA Life Sciences Annual report: Q4 2024

Mar 31, 2025, 8:05 AM EDT - 1 year ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

2024-11-29T16:15:26.000Z - 1 year ago

ENDRA Life Sciences Inc trading resumes

2024-11-29T16:10:16.000Z - 1 year ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

2024-11-22T13:11:13.000Z - 1 year ago

Endra Life Sciences regains compliance with Nasdaq

Nov 22, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 15, 2024, 4:00 PM EST - 1 year ago

ENDRA Life Sciences Quarterly report: Q3 2024

Nov 15, 2024, 4:00 PM EST - 1 year ago

ENDRA Life Sciences Earnings release: Q3 2024

Nov 15, 2024, 9:24 AM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

2024-11-07T14:40:28.000Z - 1 year ago

ENDRA Life Sciences Inc trading resumes

2024-11-07T14:35:28.000Z - 1 year ago

ENDRA Life Sciences Inc trading halted, volatility trading pause

Nov 6, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Oct 22, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Sep 17, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Sep 6, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Aug 28, 2024, 4:17 PM EDT - 1 year ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 22, 2024, 4:30 PM EDT - 1 year ago

ENDRA Life Sciences Earnings Call Transcript: Q2 2024

Aug 22, 2024, 4:30 PM EDT - 1 year ago

ENDRA Life Sciences Quarterly report: Q2 2024

Aug 22, 2024, 4:30 PM EDT - 1 year ago

ENDRA Life Sciences Earnings release: Q2 2024

Aug 22, 2024, 4:14 PM EDT - 1 year ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 16, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Reverse Stock Split

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Leadership Changes

Aug 7, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Jul 17, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 25, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 25, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 12, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Proxy statement: Proxy Filing

Jun 4, 2024, 9:21 AM EDT - 2 years ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:06 AM EDT - 2 years ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

May 31, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

ENDRA Provides Update Following In-person Meeting with FDA

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 10, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

May 7, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

Apr 19, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

ENDRA Life Sciences Earnings release: Q4 2023

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

Mar 21, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Feb 27, 2024, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 21, 2024, 8:00 AM EST - 2 years ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 14, 2024, 8:30 AM EST - 2 years ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Feb 14, 2024, 7:00 AM EST - 2 years ago

ENDRA Life Sciences Registration statement: Registration Filing

Nov 29, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 27, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

ENDRA Life Sciences Earnings release: Q3 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 7, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Aug 30, 2023, 8:00 AM EDT - 3 years ago

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Aug 23, 2023, 8:00 AM EDT - 3 years ago

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Aug 14, 2023, 4:30 PM EDT - 3 years ago

ENDRA Life Sciences Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

ENDRA Life Sciences Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

ENDRA Life Sciences Earnings release: Q2 2023

Aug 14, 2023, 4:05 PM EDT - 3 years ago

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 14, 2023, 1:30 PM EDT - 3 years ago

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

Aug 1, 2023, 8:00 AM EDT - 3 years ago

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

Buylocal Jun. 5 at 5:04 PM

$NDRA 6th time suckers took the bait.

0 · Reply

TradingTipsMaster Jun. 4 at 7:04 PM

$NDRA

0 · Reply

supplySHOCK Jun. 4 at 10:17 AM

$NDRA $MODD $BOLT $ATXG ability

0 · Reply

supplySHOCK Jun. 3 at 10:17 PM

$GURE $DXST $NDRA $MODD fuze

0 · Reply

Pagal22 May. 30 at 4:14 PM

$NDRA

0 · Reply

Pagal22 May. 30 at 4:14 PM

$NDRA

0 · Reply

yellowjacker May. 30 at 12:18 PM

0 · Reply

Finanz May. 29 at 3:51 PM

0 · Reply

focafoca99 May. 28 at 10:16 AM

$NDRA has entered a $3.8 million private placement, issuing 578,387 shares and warrants to raise capital.

0 · Reply

Run_Like_Hell May. 27 at 11:03 PM

$NDRA was burned years ago, did these losers ever get fda approval for their liver scanner thingy?

0 · Reply

STACKD0E May. 21 at 2:57 PM

$DUOT $VELO $NDRA

0 · Reply

NewsAndFilings May. 20 at 5:53 PM

Stocks to Watch: $NDRA, $SBFM, $GOVX, $HIVE, $ANY Trading Actively NOW! https://thestreetreports.com/stocks-to-watch-ndra-sbfm-govx-hive-any-trading-actively-now/

0 · Reply

NewsAndFilings May. 19 at 12:00 PM

Yesterdays Recap: $NDRA First Quarter 2026 Financial Results $ADMQ First Quarter 2026 Revenue Growth $ANY Plan of Arrangement with Cathedra Bitcoin

0 · Reply

dndodd May. 18 at 3:08 PM

$NDRA there almost out of cash at the EOM. They either need a quick raise or sell it for next to nothing. What a total disappointment.

0 · Reply

MsGrumpy May. 18 at 2:52 PM

$NDRA ENDRA Life Sciences Q1 and Provides Business Update - https://www.businesswire.com/news/home/20260518282190/en/ENDRA-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork

0 · Reply

Giants67 May. 18 at 2:08 PM

$NDRA ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update https://www.businesswire.com/news/home/20260518282190/en/ENDRA-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork

0 · Reply

NewsAndFilings May. 18 at 1:55 PM

0 · Reply

MsGrumpy May. 14 at 1:18 PM

$NDRA ENDRA Life Sciences ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility https://www.businesswire.com/news/home/20260514255247/en/ENDRA-Life-Sciences-Reports-Multi-Site-Validation-of-TAEUS-Liver-Device-Demonstrating-MRI-like-Accuracy-and-Reproducibility

0 · Reply

NewsAndFilings May. 14 at 12:29 PM

$NDRA ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility https://www.businesswire.com/news/home/20260514255247/en/ENDRA-Life-Sciences-Reports-Multi-Site-Validation-of-TAEUS-Liver-Device-Demonstrating-MRI-like-Accuracy-and-Reproducibility

0 · Reply

Giants67 May. 14 at 12:20 PM

0 · Reply

JohnGadwin May. 13 at 8:08 AM

$FCHL next one is $NDRA Low floaters on fire

0 · Reply

topstockalerts May. 13 at 1:10 AM

$NDRA there’s a certain stubbornness to this strength.

0 · Reply

Market Cap	6.06M
Revenue (ttm)	0.00
Net Income (ttm)	-7.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,400
Avg Vol	21,378
Day's Range	N/A - N/A
Shares Out	1.27M
Stochastic %K	1%
Beta	-0.04
Analysts	Sell
Price Target	$25.00